Gender Differences in Metformin's Effects on Aging and Tumor Development in Mice
Author Information
Author(s): Anisimov Vladimir N., Piskunova Tatiana S., Popovich Irina G., Zabezhinski Mark A., Tyndyk Margarita L., Egormin Peter A., Yurova Maria N., Rosenfeld Svetlana V., Semenchenko Anna V., Kovalenko Irina G., Poroshina Tatiana E., Berstein Lev M.
Primary Institution: N.N. Petrov Research Institute of Oncology, Pesochny-2, St.Petersburg, Russia
Hypothesis
Does metformin affect aging, life span, and tumorigenesis differently in male and female 129/Sv mice?
Conclusion
Metformin decreased the mean life span of male mice but slightly increased it in female mice, while also reducing malignant tumor incidence in females.
Supporting Evidence
- Metformin decreased the mean life span of male mice by 13.4%.
- Female mice treated with metformin had a 4.4% increase in mean life span.
- Metformin reduced the incidence of malignant tumors in female mice by 3.5 times.
- Male mice showed no significant change in tumor incidence with metformin treatment.
- Body weight dynamics were similar in both control and metformin-treated groups until 22 months.
Takeaway
This study looked at how a diabetes drug called metformin affects how long male and female mice live and how many tumors they get. It found that the drug made male mice live shorter lives but helped female mice live a bit longer.
Methodology
Inbred 129/Sv mice were divided into two groups, one treated with metformin and the other as a control, and various aging and tumor parameters were measured.
Limitations
The study was limited to a specific mouse strain and may not generalize to other species or strains.
Participant Demographics
Inbred 129/Sv mice, both male and female.
Statistical Information
P-Value
0.0474
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website